Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin A Cheever

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2017
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid TumorsJeffrey S Miller, Chihiro Morishima, Douglas G McNeel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid TumorsKim Margolin, Chihiro Morishima, Vamsidhar Velcheti, et al.
Journal of Translational Medicine|March 17, 2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancerDavid F Stroncek, Carolina Berger, Martin A Cheever, et al.
Nature Communications|November 19, 2021
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphomaDarci Phillips, Magdalena Matusiak, Belén Rivero Gutierrez, et al.
JAMA Oncology|June 3, 2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 StudyThomas S Uldrick, Priscila H Gonçalves, Maher Abdul-Hay, et al.
Science Translational Medicine|January 26, 2022
Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapyThomas S Uldrick, Scott V Adams, Remi Fromentin, et al.
Nature Medicine|February 12, 2026
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapyAarthi Talla, Joao L L C Azevedo, Muhammad Bilal Latif, et al.
Journal for Immunotherapy of Cancer|April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinomaPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsHolbrook E Kohrt, Paul C Tumeh, Don Benson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic CancerKatelyn T Byrne, Courtney B Betts, Rosemarie Mick, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2017
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid TumorsJeffrey S Miller, Chihiro Morishima, Douglas G McNeel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid TumorsKim Margolin, Chihiro Morishima, Vamsidhar Velcheti, et al.
Journal of Translational Medicine|March 17, 2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancerDavid F Stroncek, Carolina Berger, Martin A Cheever, et al.
Nature Communications|November 19, 2021
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphomaDarci Phillips, Magdalena Matusiak, Belén Rivero Gutierrez, et al.
JAMA Oncology|June 3, 2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 StudyThomas S Uldrick, Priscila H Gonçalves, Maher Abdul-Hay, et al.
Science Translational Medicine|January 26, 2022
Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapyThomas S Uldrick, Scott V Adams, Remi Fromentin, et al.
Nature Medicine|February 12, 2026
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapyAarthi Talla, Joao L L C Azevedo, Muhammad Bilal Latif, et al.
Journal for Immunotherapy of Cancer|April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinomaPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsHolbrook E Kohrt, Paul C Tumeh, Don Benson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic CancerKatelyn T Byrne, Courtney B Betts, Rosemarie Mick, et al.
Pageof 4